GLSINASDAQHealthcare· Biotechnology

Greenwich LifeSciences, Inc.

$26.71+1.52%(+$0.40)
TickerSpark Score
54/100
Mixed
53
Valuation
20
Profitability
15
Growth
84
Health
100
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLSI research report →

52-Week Range72% of range
Low $7.78
Current $26.71
High $34.10

Companygreenwichlifesciences.com

Greenwich LifeSciences, Inc. , a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

CEO
Snehal S. Patel
IPO
2020
Employees
4
HQ
Stafford, TX, US

Price Chart

+160.49% · this period
$33.57$20.71$7.85May 20Nov 18May 20

Valuation

Market Cap
$370.05M
P/E
-18.71
P/S
0.00
P/B
166.76
EV/EBITDA
-18.76
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-1042.76%
ROIC
-896.44%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-15,788,809 · -77.57%
EPS
$-1.21 · -75.36%
Op Income
$-16,011,817
FCF YoY
-12.16%

Performance & Tape

52W High
$34.10
52W Low
$7.78
50D MA
$24.85
200D MA
$17.83
Beta
1.39
Avg Volume
155.60K

Get TickerSpark's AI analysis on GLSI

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Jan 13, 26Patel Snehalbuy1,800
Jan 12, 26Patel Snehalbuy2,900
Dec 31, 25Patel Snehalbuy4,300
Dec 30, 25Patel Snehalbuy2,900
Dec 18, 25Patel Snehalbuy4,100
Nov 25, 25Patel Snehalbuy4,600
Nov 13, 25Patel Snehalother100,000
Nov 7, 25Patel Snehalbuy10,600
Oct 31, 25Patel Snehalbuy2,300
Apr 25, 25Patel Snehalbuy3,600

Our GLSI Coverage

We haven't published any research on GLSI yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate GLSI Report →

Similar Companies

CGTX+14.86%
Cognition Therapeutics, Inc.
$1.27
ATOS+2.32%
Atossa Therapeutics, Inc.
$4.86
TVGN+2.43%
Tevogen Bio Holdings Inc.
$10.11
ONCY+7.46%
Oncolytics Biotech Inc.
$0.83
SRZN+3.55%
Surrozen, Inc.
$26.48
HURA-2.41%
TuHURA Biosciences, Inc.
$2.40
SEER+0.89%
Seer, Inc.
$1.70
IRD+2.35%
Opus Genetics, Inc.
$4.36